Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Highly versatile immunostimulating nanocapsules for specific immune potentiation.

Vicente S, Peleteiro M, Gonzalez-Aramundiz JV, Díaz-Freitas B, Martínez-Pulgarín S, Neissa JI, Escribano JM, Sanchez A, González-Fernández A, Alonso MJ.

Nanomedicine (Lond). 2014 Oct;9(15):2273-89. doi: 10.2217/nnm.14.10.

2.

Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy.

Vicente S, Peleteiro M, Díaz-Freitas B, Sanchez A, González-Fernández Á, Alonso MJ.

J Control Release. 2013 Dec 28;172(3):773-81. doi: 10.1016/j.jconrel.2013.09.012.

PMID:
24076340
3.

A polymer/oil based nanovaccine as a single-dose immunization approach.

Vicente S, Diaz-Freitas B, Peleteiro M, Sanchez A, Pascual DW, Gonzalez-Fernandez A, Alonso MJ.

PLoS One. 2013 Apr 22;8(4):e62500. doi: 10.1371/journal.pone.0062500.

4.

Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.

Gupta NK, Tomar P, Sharma V, Dixit VK.

Vaccine. 2011 Nov 8;29(48):9026-37. doi: 10.1016/j.vaccine.2011.09.033.

PMID:
21939718
5.

Biodistribution and lymph node retention of polysaccharide-based immunostimulating nanocapsules.

Vicente S, Goins BA, Sanchez A, Alonso MJ, Phillips WT.

Vaccine. 2014 Mar 26;32(15):1685-92. doi: 10.1016/j.vaccine.2014.01.059.

PMID:
24508040
6.

Chitosan-based nanoparticles for improving immunization against hepatitis B infection.

Prego C, Paolicelli P, Díaz B, Vicente S, Sánchez A, González-Fernández A, Alonso MJ.

Vaccine. 2010 Mar 19;28(14):2607-14. doi: 10.1016/j.vaccine.2010.01.011.

PMID:
20096389
7.

Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.

Borges O, Silva M, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A.

Int Immunopharmacol. 2008 Dec 20;8(13-14):1773-80. doi: 10.1016/j.intimp.2008.08.013.

PMID:
18801462
8.

Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies.

Barhate G, Gautam M, Gairola S, Jadhav S, Pokharkar V.

Int J Pharm. 2013 Jan 30;441(1-2):636-42. doi: 10.1016/j.ijpharm.2012.10.033.

PMID:
23117021
9.
10.

An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.

Khalil SM, Tonkin DR, Snead AT, Parks GD, Johnston RE, White LJ.

J Virol. 2014 Aug;88(16):9182-96. doi: 10.1128/JVI.00327-14.

11.

The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice.

Barchfeld GL, Hessler AL, Chen M, Pizza M, Rappuoli R, Van Nest GA.

Vaccine. 1999 Feb 26;17(7-8):695-704.

PMID:
10067675
12.

Rational design of protamine nanocapsules as antigen delivery carriers.

González-Aramundiz JV, Presas E, Dalmau-Mena I, Martínez-Pulgarín S, Alonso C, Escribano JM, Alonso MJ, Csaba NS.

J Control Release. 2017 Jan 10;245:62-69. doi: 10.1016/j.jconrel.2016.11.012.

PMID:
27856263
13.

Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.

Wu CY, Chang CY, Ma HH, Wang CW, Chen YT, Hsiao PW, Chang CC, Chan CH, Liu CC, Chen JR.

Vaccine. 2014 Jul 31;32(35):4485-94. doi: 10.1016/j.vaccine.2014.06.043.

14.

Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.

Moon HJ, Lee JS, Talactac MR, Chowdhury MY, Kim JH, Park ME, Choi YK, Sung MH, Kim CJ.

Vet Microbiol. 2012 Dec 7;160(3-4):277-89. doi: 10.1016/j.vetmic.2012.05.035.

PMID:
22763171
15.

Compound DNA vaccine encoding SAG1/ SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii.

Cong H, Zhang M, Xin Q, Wang Z, Li Y, Zhao Q, Zhou H, He S.

Parasit Vectors. 2013 Mar 13;6:63. doi: 10.1186/1756-3305-6-63.

16.

Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.

Vaccine. 2008 Jul 4;26(29-30):3640-6. doi: 10.1016/j.vaccine.2008.04.071.

PMID:
18514980
17.

Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer.

Marrache S, Choi JH, Tundup S, Zaver D, Harn DA, Dhar S.

Integr Biol (Camb). 2013 Jan;5(1):215-23. doi: 10.1039/c2ib20125a.

18.

Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model.

Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, Sutcliffe J, Baker JR.

Hum Vaccin. 2010 Jul;6(7):585-94.

PMID:
20421727
19.

Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.

Pawar D, Mangal S, Goswami R, Jaganathan KS.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):550-9. doi: 10.1016/j.ejpb.2013.06.017.

PMID:
23831265
20.

Supplemental Content

Support Center